Drugs / SX-682
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06622005 | Apr 2025 → Apr 2027 expected | plasma cell myeloma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT04477343 | Nov 2020 → May 2026 overdue | pancreatic ductal adenocarcinoma | University of Rochester | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04245397 | Jun 2020 → Mar 2028 expected | myelodysplastic syndrome | Syntrix Biosystems, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT03161431 | Jun 2019 → Aug 2026 overdue | metastatic melanoma | Syntrix Biosystems, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07667400 | Jul 2026 → Oct 2036 expected | adenoid cystic carcinoma, castration-resistant prostate carcinoma, hypopharyngeal carcinoma, laryngeal carcinoma +5 | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07002320 | Apr 2025 → Oct 2029 expected | prostate carcinoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06149481 | Mar 2024 → Oct 2027 expected | colorectal cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04574583 | Nov 2020 → Feb 2023 | metastatic malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT04599140 | Oct 2020 → Jul 2026 overdue | colon adenocarcinoma, rectum adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07322341 | Sep 2026 → Nov 2030 expected | non-small cell lung carcinoma | University of Washington | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06228053 | Nov 2024 → Jun 2027 expected | prostate carcinoma | Syntrix Biosystems, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05604560 | Nov 2023 → Sep 2026 expected | pancreatic adenocarcinoma | Lei Zheng | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05570825 | Apr 2023 → Jul 2027 expected | non-small cell lung carcinoma | University of Washington | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SX-682 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05604560 ↗ |
| Action | Inhibit | “SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)” NCT03161431 ↗ |
| Modality | Small molecule | “SX-682 is an oral small molecule selective inhibitor” NCT03161431 ↗ |
| Route | Oral | “SX-682 is an oral small molecule” NCT03161431 ↗ |
| Target | CXCR1 | “selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1)” NCT03161431 ↗ |